Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 3
2011 2
2012 2
2014 1
2015 2
2017 4
2018 3
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.
Kameda T, Shide K, Tahira Y, Sekine M, Sato S, Ishizaki J, Takeuchi M, Akizuki K, Kamiunten A, Shimoda H, Toyama T, Maeda K, Yamashita K, Kawano N, Kawano H, Hidaka T, Yamaguchi H, Kubuki Y, Kitanaka A, Matsuoka H, Shimoda K. Kameda T, et al. Among authors: shimoda h. Viruses. 2022 Mar 29;14(4):710. doi: 10.3390/v14040710. Viruses. 2022. PMID: 35458440 Free PMC article.
TET2 mutation in diffuse large B-cell lymphoma.
Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: shimoda h. J Clin Exp Hematop. 2017;56(3):145-149. doi: 10.3960/jslrt.56.145. J Clin Exp Hematop. 2017. PMID: 28331128 Free PMC article.
TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
Shimoda K, Shide K, Kameda T, Hidaka T, Kubuki Y, Kamiunten A, Sekine M, Akizuki K, Shimoda H, Yamaji T, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A. Shimoda K, et al. Among authors: shimoda h. J Clin Exp Hematop. 2015;55(3):145-9. doi: 10.3960/jslrt.55.145. J Clin Exp Hematop. 2015. PMID: 26763362 Free article.
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.
Sekine M, Kameda T, Shide K, Maeda K, Toyama T, Kawano N, Takeuchi M, Kawano H, Sato S, Ishizaki J, Kukita T, Kamiunten A, Akizuki K, Tahira Y, Shimoda H, Hidaka T, Yamashita K, Matsuoka H, Kitanaka A, Kubuki Y, Shimoda K. Sekine M, et al. Among authors: shimoda h. Eur J Haematol. 2021 Mar;106(3):398-407. doi: 10.1111/ejh.13565. Epub 2020 Dec 19. Eur J Haematol. 2021. PMID: 33301622
Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, Maeda K, Sato S, Ishizaki J, Kawano H, Kamiunten A, Akizuki K, Tahira Y, Shimoda H, Shide K, Hidaka T, Kitanaka A, Yamashita K, Matsuoka H, Shimoda K. Sekine M, et al. Among authors: shimoda h. Eur J Haematol. 2017 May;98(5):501-507. doi: 10.1111/ejh.12863. Epub 2017 Mar 10. Eur J Haematol. 2017. PMID: 28152225
Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A, Shide K, Kameda T, Ito M, Sekine M, Kubuki Y, Hidaka T, Akizuki K, Tahira Y, Toyama T, Kawano N, Marutsuka K, Maeda K, Takeuchi M, Kawano H, Sato S, Ishizaki J, Shimoda H, Yamashita K, Matsuoka H, Shimoda K. Kamiunten A, et al. Among authors: shimoda h. Int J Hematol. 2018 Oct;108(4):411-415. doi: 10.1007/s12185-018-2495-2. Epub 2018 Jul 9. Int J Hematol. 2018. PMID: 29987745
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y, Shide K, Kameda T, Yamaji T, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hashimoto K, Yamamoto S, Hasuike S, Hidaka T, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: shimoda h. Ann Lab Med. 2017 Mar;37(2):159-161. doi: 10.3343/alm.2017.37.2.159. Ann Lab Med. 2017. PMID: 28029004 Free PMC article. No abstract available.
Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation.
Matsunaga T, Fukai F, Kameda T, Shide K, Shimoda H, Torii E, Kamiunten A, Sekine M, Yamamoto S, Hidaka T, Kubuki Y, Yokokura S, Uemura M, Matsuoka A, Waki F, Matsumoto K, Kanaji N, Ishii T, Imataki O, Dobashi H, Bandoh S, Shimoda K. Matsunaga T, et al. Among authors: shimoda h. Ann Hematol. 2012 Oct;91(10):1633-43. doi: 10.1007/s00277-012-1498-y. Epub 2012 May 29. Ann Hematol. 2012. PMID: 22644786
R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, Fang S, Liu C, Gelman M, Lang W, Romero J, McLaughlin J, Bhamidipati S, Clough J, Low C, Reitsma A, Siu S, Pine P, Park G, Torneros A, Duan M, Singh R, Payan DG, Matsunaga T, Hitoshi Y, Shimoda K. Shide K, et al. Among authors: shimoda hk. Blood. 2011 Jun 23;117(25):6866-75. doi: 10.1182/blood-2010-01-262535. Epub 2011 Apr 29. Blood. 2011. PMID: 21531978 Free article.
20 results